Effects of @entity5832 on the sleep of @entity1 with anergic XXXX .

@entity1 @entity162 @entity2147 @entity5832 @entity1154 @entity1319
A significant proportion of @entity1 with @entity162 are @entity2147 . It is not clear if this affects response to treatment because few studies have systematically examined treatment effects on sleep in @entity1 with @entity162 . Reported herein are the results of what we believe to be the first study of the effects of the @entity1154 oxidase inhibitor @entity5832 (average dose=37 mg/day) on the sleep of @entity1 with @entity162 .Twenty-three @entity1 with anergic @entity162 completed sleep studies before and after pharmacotherapy. Changes in polysomnographic variables were examined using paired t tests. The @entity1 experienced a 40% reduction in @entity1319 ( @entity1319 ) sleep time, as well as significant decreases in @entity1319 percentage, @entity1319 activity, number of @entity1319 periods, and @entity1319 intensity. @entity1319 latency was prolonged by nearly 3-fold. The decrease in @entity1319 sleep was accompanied by a modest (8%) reduction in total sleep time and increased "light" sleep. There was no change in sleep continuity indices or slow wave sleep. Correlational analyses suggested that antidepressant response was only weakly associated with changes in @entity1319 sleep. These findings indicate that @entity5832 's effects on @entity1319 sleep greatly surpass effects on sleep architecture or sleep maintenance. Moreover, effective treatment of @entity162 did not "normalize" the @entity2147 associated with @entity162 .
